Get the Stockscreener App
206.78
0.00%
-0.40
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $206.78, with a volume of 89,253.
It is down -0.00% in the last 24 hours and down -7.80% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$207.18
Open:
$207.19
24h Volume:
89,253
Relative Volume:
0.01
Market Cap:
$366.22B
Revenue:
$61.16B
Net Income/Loss:
$4.19B
P/E Ratio:
87.57
EPS:
2.3614
Net Cash Flow:
$17.82B
1W Performance:
+0.46%
1M Performance:
-7.80%
6M Performance:
-6.09%
1Y Performance:
+2.92%
1-Day Range:
$206.65
$207.60
1-Week Range:
$201.80
$209.68
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
207.12 | 366.33B | 61.16B | 4.19B | 17.82B | 2.3614 |
LLY
Lilly Eli Co
|
910.25 | 818.59B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
239.79 | 577.90B | 94.19B | 26.80B | 19.70B | 11.05 |
MRK
Merck Co Inc
|
119.34 | 295.13B | 64.93B | 18.26B | 12.36B | 7.2751 |
AZN
Astrazeneca Plc
|
184.53 | 290.22B | 58.80B | 10.24B | 8.98B | 3.2788 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie, Novartis Sue Wash. Over New 340B Drug-Pricing Law - Law360
How AbbVie’s official partnership with MLB will unfold over the course of the season - Medical Marketing and Media
AbbVie (NYSE:ABBV) Expands Awareness And Psychedelic Research Russell 1000 - Kalkine Media
Is AbbVie Inc. (ABBV) one of the debt free halal stocks to buy? - MSN
Market Outlook: Can AbbVie Inc stock double in the next yearTrend Reversal & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Investors heavily search AbbVie Inc. (ABBV): Here is what you need to know - MSN
AbbVie Inc stock faces renewed scrutiny as Mercy Investment files shareholder proposal amid pipeline - AD HOC NEWS
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know - Yahoo Finance
LLY or ABBV: Which Drugmaker is Likely to Offer Better Upside in 2026? - TradingView
AbbVie stock price forecast for 2040: Immunology pipeline and oncology expansion support long-term path toward $550 - Traders Union
Pensionfund Sabic Invests $4.02 Million in AbbVie Inc. $ABBV - MarketBeat
Meadowbrook Wealth Management LLC Grows Stake in AbbVie Inc. $ABBV - MarketBeat
DAVENPORT & Co LLC Sells 5,545 Shares of AbbVie Inc. $ABBV - MarketBeat
62,112 Shares in AbbVie Inc. $ABBV Bought by E. Ohman J or Asset Management AB - MarketBeat
Is AbbVie (ABBV) one of the Best Psychedelic Stocks to Buy in 2026? - Insider Monkey
AbbVie Inc stock faces activist pressure as Mercy Investment files shareholder proposal amid pipelin - AD HOC NEWS
AbbVie’s sports marketing move - eMarketer
AbbVie Inc. stock faces activist pressure as Mercy Investment files shareholder proposal amid pipeli - AD HOC NEWS
AbbVie Named Official Pharmaceutical Partner of Major League Baseball - Investing News Network
AbbVie Stock Outlook 2026: Performance, Valuation, and Dividend YieldNews and Statistics - IndexBox
AbbVie partners with MLB to boost cancer nonprofit donations through expanded campaign - Traders Union
Protagonist Partners With Johnson & Johnson To Compete With AbbVie's Skyrizi - Seeking Alpha
AbbVie (ABBV) Teams Up with MLB in Nationwide Cancer Initiative - GuruFocus
What Is Considered a Good Stock Dividend? 2 Healthcare Stocks Fit the Bill. - The Motley Fool
Overbrook Management Corp Acquires New Holdings in AbbVie Inc. $ABBV - MarketBeat
SG Americas Securities LLC Sells 831,382 Shares of AbbVie Inc. $ABBV - MarketBeat
Breast Implants Market Is Booming So Rapidly | Abbvie, Inc., Ideal Implant Incத் - openPR.com
5,856 Shares in AbbVie Inc. $ABBV Acquired by Clear Trail Advisors LLC - MarketBeat
AbbVie Inc. $ABBV is BDF Gestion's 10th Largest Position - MarketBeat
Assenagon Asset Management S.A. Sells 267,547 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Stock Slides -7.5% With A 5-Day Losing Spree - Trefis
5-Day Sell-Off Sends AbbVie Stock Down 7.5% - Trefis
Mercy Investment Submits a Shareholder Proposal to AbbVie - marketscreener.com
AbbVie : 2025 Annual Report on Form 10-K and 2026 Proxy Statement - marketscreener.com
Strong decade for AbbVie (NYSE: ABBV) as 2026 proxy outlines returns, pay and governance - Stock Titan
AbbVie Escapes Ill. Genetic Privacy Lawsuit - Law360
Why AbbVie Stock Looks Like a Dirt Cheap Buy Right Now - The Motley Fool
AbbVie Inc. $ABBV Shares Purchased by Wealth Enhancement Advisory Services LLC - MarketBeat
AbbVie Inc. $ABBV Stake Reduced by Gradient Investments LLC - MarketBeat
Nordea Investment Management AB Has $950.63 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie, Inc. Trade Ideas — LSX:A1J84E - TradingView
AbbVie Inc. $ABBV Shares Acquired by Procyon Advisors LLC - MarketBeat
MassMutual Private Wealth & Trust FSB Has $39.20 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
Hamlin Capital Management LLC Has $213.68 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
Aventura Private Wealth LLC Buys $2.14 Million Stake in AbbVie Inc. - National Today
CWA Asset Management Group LLC Purchases 11,964 Shares of AbbVie Inc. $ABBV - MarketBeat
Aventura Private Wealth LLC Takes $2.14 Million Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Stock: Here’s Why Street Sets a $249 Mean Target - TIKR.com
AbbVie Stock Slides as Insider Selling Spooks Investors - TipRanks
AbbVie Inc. $ABBV Shares Sold by TruWealth Advisors LLC - MarketBeat
Neville Rodie & Shaw Inc. Has $23.31 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.84%
1.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):